LY 01013

Drug Profile

LY 01013

Alternative Names: LY-01013

Latest Information Update: 06 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Luye Pharma Group
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Immunomodulators; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Tryptophan oxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bladder cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Renal cancer

Most Recent Events

  • 26 Feb 2018 Luye Pharma Group files for patent protection with China FDA for LY 01013 before February 2018
  • 26 Feb 2018 Preclinical trials in Bladder cancer, Head and neck cancer, Lung cancer, Malignant melanoma, and Renal cancer in China (PO) before February 2018
  • 26 Feb 2018 China FDA accepts clinical trial application for LY 01013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top